Sex Differences in HIV Infection: Mystique Versus Machismo

Scully, Eileen P.

doi:10.20411/pai.v3i1.238

Cited by 10 publications

(6 citation statements)

References 164 publications

(183 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, many of these lifestyle factors are enriched among PWH [11][12][13][14]. Residual immune activation and inflammation, and some other key drivers, may differ between men and women [15], racial/ethnic groups [16], and geographic regions [17] and are likely to be influenced by genetic and environmental factors as well. The list of candidate drivers described here is likely incomplete and requires further study in PWH and uninfected populations to identify root drivers and their relative importance in different settings.…”

Section: Can We Develop Therapeutics To Reduce Immune Activation/inflammation and What Should Be The Main Targets For Such Interventions?mentioning

confidence: 99%

Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop

Gabuzda

Jamieson

Collman

et al. 2020

PAI

View full text Add to dashboard Cite

People with HIV (PWH) experience accentuated biological aging, as defined by markers of inflammation, immune dysfunction, and the epigenetic clock. They also have an elevated risk of multiple age-associated comorbidities. To discuss current knowledge, research gaps, and priorities in aging and age-related comorbidities in treated HIV infection, the NIH program staff organized a workshop held in Bethesda, Maryland in September 2019. This review article describes highlights of discussions led by the Pathogenesis/Basic Science Research working group that focused on three high priority topics: immunopathogenesis; the microbiome/virome; and aging and senescence. We summarize knowledge in these fields and describe key questions for research on the pathogenesis of aging and age-related comorbidities in PWH. Understanding the drivers and mechanisms underlying accentuated biological aging is a high priority that will help identify potential therapeutic targets to improve healthspan in older PWH.

show abstract

Section: Can We Develop Therapeutics To Reduce Immune Activation/inflammation and What Should Be The Main Targets For Such Interventions?mentioning

confidence: 99%

Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop

Gabuzda

Jamieson

Collman

et al. 2020

PAI

View full text Add to dashboard Cite

show abstract

“…In COVID-19 pandemic we have been able to clearly observe sex differences in the immune response to the virus, and how these translate into clinical outcomes (195). Differences in the acquisition of HIV and in disease pathogenesis between men and women have long been also reported in epidemiological studies (196,197).…”

Section: Sex Differences In Immune Responsesmentioning

confidence: 92%

Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention

et al. 2022

View full text Add to dashboard Cite

Preventing new HIV infections remains a global challenge. Young women continue to bear a disproportionate burden of infection. Oral pre-exposure prophylaxis (PrEP), offers a novel women-initiated prevention technology and PrEP trials completed to date underscore the importance of their inclusion early in trials evaluating new HIV PrEP technologies. Data from completed topical and systemic PrEP trials highlight the role of gender specific physiological and social factors that impact PrEP uptake, adherence and efficacy. Here we review the past and current developments of HIV-1 prevention options for women with special focus on PrEP considering the diverse factors that can impact PrEP efficacy. Furthermore, we highlight the importance of inclusion of female scientists, clinicians, and community advocates in scientific efforts to further improve HIV prevention strategies.

show abstract

“…Women are at a higher risk of HIV seroconversion when engaging in heterosexual sexual behavior than men. This may be in part due to inflammation at the cervico-vaginal mucosa lowering the barrier to HIV infection [33]. Although in early infection, women seem to have slightly lower viral loads, disease progression is comparable in men and women.…”

Section: Illness Progressionmentioning

confidence: 99%